Kelonia is a company working on genetic medicine, using their Kelonia Therapeutics Platform with iGPS® technology to efficiently deliver genetic cargo to desired tissues.

Kelonia

Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal of bringing genetic medicines to every patient in need.

Venrock

Horizons Ventures

Alta Partners

Kelonia Therapeutics

Last month, we had the privilege of hosting Dr. Kristen Hege, Kelonia board member and trailblazer in the field of cell therapy, for an inspiring leadership talk!
 
Dr. Hege shared profound insights from her journey hiking the Pacific Coast Trail, drawing compelling parallels to her pioneering work in CAR T-cell therapies. Her reflections on leadership, perseverance, and embracing challenges left a lasting impact on all who attended and continues to resonate with our team as we continue our work advancing our own lead in vivo CAR T program to the clinic.

We had a blast partnering with teammates from Special Olympics Massachusetts at last week’s Bio-Ball 2024 fundraiser and basketball tournament. We came together to #playunified and raise money for a great cause alongside our biotech industry peers. Team Kelonia proudly raised $16,378 for Special Olympics Massachusetts, putting us in 3rd place in the fundraising challenge, and securing our chance to play on the parquet floor at TD Garden with our teammates from Special Olympics Lynn & Haverill!  
 
Learn more about how you can support: https://lnkd.in/gBB2QkVP.  #ChooseToInclude #PlayUnified

We look forward to presenting preclinical data from our lead #invivo #CART candidate, KLN-1010, in #MultipleMyeloma at the American Association for Cancer Research Annual Meeting 2024 in San Diego. Stop by our poster presentation to learn more about the therapeutic potential of KLN-1010 and the promise of our iGPS® technology for #geneticmedicines.  
 
See details of our poster here: https://lnkd.in/gYq-Pz6f 
 
#AACR24

Our #2023HolidayParty was last week, after the holidays! This not only gave us something to look forward to in January, but it also allowed us to really let our hair down because it's a (slightly) less hectic time than the holidays. Congratulations to Jose Sanabria and Joshua Daniel, the winners of our ugly sweater contests!  Huge thanks to our neighbors, Capo Restaurant & Supper Club, for hosting us! It was a beautiful location with delicious food, and we had a great time!

Our Vice President, Strategy and Business Development, Bharat Reddy, is attending Biotechnology Innovation Organization’s #BIO2024. Connect with us in sunny San Diego, to learn more about our iGPS® platform exciting work advancing #invivo CAR-T therapies for cancer: https://lnkd.in/eEDtKaAK.

#HappyNewYear! We kicked off 2024 by bringing donations from our 2nd annual clothing drive to St. Francis House. Please consider donating new or gently-used clothes to your local shelter (especially outerwear!) to help your unhoused neighbors keep warm during these cold winter months.

Metric
Company Name	Kelonia
Symbol
MSH ID	COM:KELONIATX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	57
Website	keloniatx.com
LinkedIn	kelonia-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

KELO

COM:KELONIATX

Kelonia

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue